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Background: Recent findings suggest that the pathological effects of apoE4, the most prevalent genetic risk factor
for Alzheimer’s disease (AD), start many years before the onset of the disease and are already detectable at a young
age. In the present study we investigated the extent to which such pathological and cognitive impairments also
occur in young apoE4 mice.
Results: This study revealed that the levels of the presynaptic glutamatergic vesicular transporter, VGlut, in the CA3,
CA1, and DG hippocampal subfields were lower in hippocampal neurons of young (4-month-old) apoE4-targeted
replacement mice than in those of the apoE3 mice. In contrast, the corresponding inhibitory GABAergic nerve
terminals and perikarya were not affected by apoE4.
This synaptic effect was associated with hyperphosphorylation of tau in these neurons. In addition, apoE4 increased
the accumulation of neuronal Aβ42 and induced mitochondrial changes, both of which were specifically
pronounced in CA3 neurons. Spatial navigation behavioral studies revealed that these hippocampal pathological
effects of apoE4 are associated with corresponding behavioral impairments. Time-course studies revealed that the
effects of apoE4 on tau hyperphosphorylation and the mitochondria were already apparent at the age of 1 month
and that the apoE4-driven accumulation of neuronal Aβ and reduced VGlut levels evolve later and are apparent at
the age of 2–4 months. Furthermore, the levels of tau phosphorylation decrease in apoE3 mice and increase in
apoE4 mice between 1 and 4 months, whereas the levels of Aβ42 decrease in apoE3 mice and are not affected in
apoE4 mice over the same time period.
Conclusions: These findings show that apoE4 stimulates the accumulation of Aβ42 and hyperphosphorylated tau
and reduces the levels of VGlut in hippocampal neurons of young apoE4-targeted replacement mice and that these
neurochemical effects are associated with cognitive impairments. This model is not associated with hypothesis-driven
mechanistic manipulations and is thus most suitable for unbiased studies of the mechanisms underlying the
pathological effects of apoE4.Introduction
Alzheimer’s disease (AD), the most prevalent form of de-
mentia in the elderly, is characterized by cognitive de-
cline and by the occurrence of brain senile plaques and
neurofibrillary tangles (NFT) as well as by the loss of brain
synapses and neurons [1-3]. The senile plaques contain a* Correspondence: dmichael@post.tau.ac.il
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reproduction in any medium, provided the or40-42-amino acid-long amyloid-beta (Aβ) peptide derived
from a precursor protein (APP) [3,4]. Aβ is also present in
the brain as soluble oligomers, which play an important
and early role in neurodegeneration in AD [5-8]. The
NFT contain abnormal aggregates of the microtubule-
associated protein, tau, which leads to disruption of the
neuronal cytoskeleton followed by neurodegeneration and
cell death [9,10]. Several chemical modifications have been
described in NFT's tau, of which hyperphosphorylation
is a key event [11,12]. The classical neuropathological
studies of Braak & Braak revealed that the AD lesions
begin to form 20–30 years before the disease becomesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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longitudinal imaging studies, which revealed that brain at-
rophy and Aβ deposition begin during the preclinical
stage of the disease [14-17]. Synaptic dysfunction and loss
is the earliest histological neuronal pathology in AD and
is associated with early loss of dendritic spines and with
presynaptic and postsynaptic impairments [18,19], which
correlate with cognitive decline at the early stages of the
disease [20]. The synaptic pathology is particularly pro-
nounced in distinct brain areas such as the hippocampus.
Genetic studies revealed allelic segregation of the apo-
lipoprotein E (apoE) gene to families with a higher risk
of late-onset AD and of sporadic AD [21-23]. There are
three major alleles of apoE, termed E2 (apoE2), E3
(apoE3), and E4 (apoE4), of which apoE4 is the AD risk
factor. The frequency of apoE4 in sporadic AD is >50%,
and it increases the risk for AD by lowering the age of
onset of the disease by 7 to 9 years per allele copy [22].
Pathologically, apoE4 is associated with increased depo-
sition of Aβ [24,25], hyperphosphorylation of tau [26,27],
as well as impaired neuronal plasticity and neuropathol-
ogy [28,29]. Declining memory and brain pathology have
been reported in middle-aged apoE4 carriers with an on-
going normal clinical status [30,31], suggesting that the
effects of apoE4 begin decades before the onset of AD.
The finding that Aβ deposition is specifically elevated in
apoE4-positive AD patients [25], combined with in vivo
and in vitro model studies, which revealed that apoE4 and
the amyloid cascade interact synergistically [12,32-36], led
to the suggestion that the pathological effects of apoE4 are
mediated via cross-talk with the amyloid cascade [37-40].
The central role of apoE in the transport and delivery of
brain lipids and the finding that the binding of apoE to
lipoproteins is affected by the apoE genotype [41] led to
the proposal that the pathological effects of apoE4 are
mediated via lipid-related mechanisms, possibly through
the effects of lipids on neural and synaptic function and
morphology. ApoE is expressed in stressed and injured
neurons [42] and transgenic over-expression of apoE4 in
neurons increases tau phosphorylation [43,44]. This led to
an additional hypothesis, namely, that the pathological
effects of apoE4 are mediated by intraneuronal Aβ and
stimulation of tau hyperphosphorylation [43].
Accumulating evidence suggest that mitochondrial
dysfunction occurs early in AD and plays a key role in
the disease [45]. In vivo and in vitro model studies re-
vealed that the pathological effects of apoE4 are associ-
ated with enhanced mitochondrial pathology, such as
decreased activity of mitochondrial enzymes, specifically,
cytochrome C oxidase (COX) [46,47]. Recent studies sug-
gest that regions within the gene coding for the translocase
of the outer mitochondrial membrane, Tom40, and the
apoE gene interact genetically and share common en-
hancers [48]. Taken together, these findings suggest thatthe mitochondria are an early and important intracellular
target of apoE4.
The existence of several suggested mechanisms has
important implications regarding the design and use of
appropriate apoE4-related in vivo models. Accordingly,
models such as APP and apoE4 double transgenic mice
[49] and pharmacological activation of the amyloid cascade
in apoE4 mice [32,33] are most suitable for assessing the
role of cross talk interactions between apoE4 and the amy-
loid cascade, whereas mice in which apoE4 is expressed
preferentially in neurons [50] are suitable for studying the
pathological consequences of intraneuronal apoE4 and its
catabolites and their interactions with tau. In view of the
numerous apoE4-related mechanistic hypotheses, it is im-
portant to develop and employ “mechanistically unbiased”
models in which the pathological effects of apoE4 are not
triggered by exposure to a theory and a mechanistic
hypothesis-driven paradigm. Since the pathological effects
of apoE4 in humans begin many years before the onset of
the disease and are already detectable at a young age, a
possible application of this hypothesis-independent ap-
proach is to focus on the early effects of apoE4.
In the present study we adopted this approach utilizing
young 4-month-old targeted replacement mice free of any
exterior manipulations. In view of the documented pre-
synaptic and mitochondria-related effects of apoE4 and
the cross talk between apoE4 and tau [32,33,49,50], the
study focuses on these parameters and on assessing the
extent to which these effects are associated with cognitive
impairments and the age at which they evolve.
Materials and methods
Transgenic mice
ApoE-target replacement mice, in which the endogenous
mouse apoE was replaced by either human apoE3 or
apoE4, were created by gene targeting, as previously de-
scribed [51]. The mice used were purchased from Taconic
(Germantown, NY). Mice were back-crossed to wild-type
C57BL/6J mice (Harlan 2BL/610) for ten generations and
were homozygous for the apoE3 (3/3) or apoE4 (4/4) al-
leles. These mice are referred to in the text as apoE3 and
apoE4 mice, respectively. The apoE genotype of the mice
was confirmed by PCR analysis, as described previously
[33,52]. All the experiments were performed on age-
matched male animals (1 to 4 months of age), and were
approved by the Tel Aviv University Animal Care Com-
mittee. Every effort was made to reduce animal stress and
to minimize animal usage.
Immunohistochemistry and immunofluorescence confocal
microscopy
Mice were anesthetized with ketamine and xylazine and
perfused transcardially with saline and then with 4%
paraformaldehyde in 0.1M phosphate buffer, pH 7.4.
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formaldehyde in 0.1 M phosphate buffer, pH 7.4, and
then placed in 30% sucrose for 48 h. Frozen coronal sec-
tions (30 μm) were then cut on a sliding microtome, col-
lected serially, placed in 200 μl of cryoprotectant, and
stored at −20°C until use. The free-floating sections were
immunostained with the following primary antibodies
(Abs): Rabbit anti-Aβ42 (1:500; Chemicon, Temecula, CA);
Rabbit anti-Aβ40 (1:500; Chemicon); Mouse anti-pan Aβ
(4G8, 1:100; Signet); Mouse anti-N-terminal APP (22C11,
1:2000, Millipore); Rabbit anti-tau (H150 ,1:600, Santa Cruz
Biotechnology); Rabbit anti-202/205 phosphorylated tau
(AT8 ,1:200, Innogenetics); Mouse anti-212/214 phosphor-
ylated tau (AT100 ,1:200, Innogenetics); Rabbit anti-Tom40
(1:500; Santa Cruz); Goat anti-COX1 (1:400; Santa Cruz);
Guinea-pig anti-VGlut1 (1:2000; Millipore); Mouse anti-
GAD67 (1:250; Millipore); Mouse anti-Vgat (1:200; Synaptic
Systems); Mouse anti-Synaptophysin (1:200; Sigma); Mouse
anti-NeuN (1:500; Chemicon); Goat anti-apoE (1:5000,
Chemicon) and Mouse anti-GFAP (1:2000, Pharmingen).
Immunohistochemistry was performed as previously
described [32]. Accordingly, sections were washed with
10 mM PBS, pH 7.4, and blocked for 1 h in 20% serum
diluted in PBS with 0.1% Triton X-100 (PBST), after
which the primary antibody, diluted in PBST containing
2% of the appropriate serum, was applied overnight at 4°C.
The sections were then rinsed in PBST, and incubated for
1 h at room temperature with the corresponding second-
ary antibody (Vector Laboratories, Burlingame, CA) di-
luted 1:200 in PBST containing 2% of the appropriate
serum. After several additional rinses in PBST, the sections
were incubated for 0.5 h in avidin-biotin-horseradish per-
oxidase complex (ABC Elite; Vector Laboratories) in
PBST. After rinses in PBST, sections were placed for up to
10 min in diaminobenzidine chromagen solution (Vector
Laboratories). To minimize variability, sections from all
animals were stained simultaneously. The reaction was
monitored visually and stopped by rinses in PBS. The
sections were mounted on a dry gelatin-coated slide and
then dehydrated and sealed with cover slips. Aβ staining
was performed similarly except that the sections were
preincubated with 70% formic acid for 7 min in order to
increase antigen retrieval prior to staining. The immuno-
stained sections were viewed using a Zeiss light micro-
scope (Axioskop, Oberkochen, Germany) interfaced with
a CCD video camera (Kodak Megaplus, Rochester, NY,
USA). Pictures of stained brains were obtained at X10
magnification. Analysis and quantification of the staining
(2 hippocampal images per animal at Bregma (−1.7)-
(−2.06)) were performed using the Image-Pro plus system
for image analysis (v. 5.1, Media Cybernetics, Silver Spring,
MD, USA). The images were analyzed by marking the area
of interest (e.g., a hippocampal subfield such as CA3) and
setting a threshold for all sections of a specific labeling.The stained area above the threshold relative to the total
area was then determined for each section. All the groups
were stained together and the results presented represent
the mean ± SEM of the percent area stained normalized
relative to the young apoE3 mice.
Immunofluorescence staining was performed using
fluorescent chromogens. Accordingly, sections were first
blocked (incubation with 20% normal donkey serum in
PBST for 1 h at room temperature), and then reacted for
48 h at 4°C with the primary antibodies (dissolved in 2%
normal donkey serum in PBST). Next, the bound primary
antibodies were visualized by incubating the sections for
1 h at room temperature with Alexa-fluor 488-conjugated
donkey anti-rabbit (1:1000; Invitrogen, Eugene, OR),
Alexa-fluor 488-conjugated donkey anti-mouse (1:1000;
Invitrogen), or Alexa-fluor 488-conjugated goat anti-
Guinea-pig (1:1000; Invitrogen), depending on the appro-
priate initial antibody. The sections were then mounted
on dry gelatin-coated slides. Sections stained for immuno-
fluorescence were visualized using a confocal scanning
laser microscope (Zeiss, LSM 510). Images (1024×1024
pixels, 12 bit) were acquired by averaging eight scans.
Control experiments revealed no staining in sections lack-
ing the first antibody. The intensities of immunofluores-
cence staining, expressed as the percentage of the area
stained, were calculated utilizing the Image-Pro Plus sys-
tem (version 5.1, Media Cybernetics) as previously de-
scribed [32]. All images for each immunostaining were
obtained under identical conditions, and their quantita-
tive analyses were performed with no further handling.
Moderate adjustments for contrast and brightness were
performed evenly on all the presented images of the dif-
ferent mouse groups. The images were analyzed by setting
a threshold for all sections of a specific labeling. The area
of the staining over the threshold compared to the total
area of interest was determined for each mouse and each
group was averaged. For the apoE, GFAP and NeuN triple
labeling colocalization experiments, each image was first
analyzed separately. The colocalizations of apoE with
NeuN and of apoE with GFAP were then determined as
the percentage of the co-stained area relative to the stain-
ing of each of the individual stainings.
Immunoblot analysis
Immunoblot analysis was performed as previously de-
scribed [53,54]. In brief, mice were decapitated and their
brains were rapidly excised and frozen in liquid nitrogen.
The frozen brains were then cut into 500-μm coronal slices
utilizing a frozen mold, after which the whole hippocampi
or its corresponding CA3 subfield were excised while fro-
zen and stored at −70°C until use. The dissected hippo-
campus and CA3 samples of each brain were then
homogenized in 200 μl or 50 μl, respectively, in the follow-
ing detergent-free homogenization buffer [10 mM HEPES,
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tor cocktail (Sigma P8340) and phosphatase inhibitor cock-
tail (Sigma P5726)]. The homogenates were then aliquoted
and stored at −70°C. Gel electrophoresis and immunoblot
assays were performed on SDS-treated samples (boiling for
10 min in 0.5% SDS) as previously described [32,53] utiliz-
ing the following antibodies: Mouse anti-VGlut1 (1:1000;
Millipore), Rabbit anti-Tom40 (1:1000; Santa Cruz), Mouse
anti-COX1 (1:1000; Santa Cruz), and Goat anti-apoE
(1:10000, Chemicon). Protein concentration was deter-
mined utilizing the BCA protein assay kit (Pierce 23225).
The immunoblot bands were visualized utilizing the
ECL chemiluminescent substrate (Pierce), after which
their intensity was quantified using EZQuantGel soft-
ware (EZQuant, Tel Aviv, Israel). GAPDH levels were
employed as gel loading controls and the results are
presented relative to the apoE3 mice.
Aβ42 ELISA
The levels of mouse Aβ X-42 (Aβ42) were determined util-
izing the Beta Amyloid X-42 ELISA kit from Covance
(Cat# SIG-38954) according to the manufacturer's specifi-
cations. Specifically, whole hippocampi were homogenized
in 180 μl Tris buffered saline (20 mM Tris, pH 7.4,
containing 150 mM NaCl; TBS) with protease inhibitor
(Roche). Triton X-100 was then added to a final concen-
tration of 1% and the samples were agitated by pipetting
up and down.
Behavioral experiments
The spatial navigation test was performed by a dry maze
modification of the hole board test [32,55], which monitors
the ability of the mice to locate a small water-filled well in a
circular arena. The mice were water deprived for 2 days be-
fore the experiment, whereas throughout the entire experi-
ment they were subjected to a 23 h per day water
deprivation regime, in which they were able to drink ad
libium for 1 h every day after being tested. After 2 days of
water deprivation, the mice were placed in a circular arena
(95 cm diameter, with 20 evenly separated wells; 1 cm
depth, 0.5 cm diameter) in which all the wells were filled
with 100 μl of water. This was performed 4 times per day
for 2 days. Each such run lasted 120 sec, during which the
mice were allowed to drink from all the wells that they lo-
cated during these runs. The arena was cleaned with 70%
ethanol between each run. Following this habituation, the
mice were placed in the arena, in which only 1 well
contained water (4 runs a day, each lasting up to 120 sec).
If the mouse found the water-filled well, it was allowed to
drink for 15 sec; if the mouse did not find the well, it was
brought to it after 120 sec and allowed to remain there for
15 sec. The time required for the mice to reach the well (la-
tency) was measured in seconds. This was performed for 8
days. To elevate the level of complexity of the test, thelocation of the water-filled well was changed to a novel lo-
cation on day 9, and the performance of the mice was
tested for 5 more days in this configuration. Latency to the
water-filled well was measured for each trial.
Statistical analysis
The immunohistochemistry results were obtained utilizing
two sets of apoE3 and apoE4 mice, which respectively
contained 8 and 12 animals for each group, except for the
Tom40 experiment in which one set of mice (n=8) was
employed. The results obtained with the two different
cohorts were similar when analyzed separately and are
presented jointly (means ± SEM) following normalization
of each of the experiments to apoE3 = 100%. The immu-
noblot results (n=10 for all the hippocampal samples and
n=5 for the CA3 samples) consisted of at least three blots
and are expressed as percentages of the levels of the apoE3
mice (means ± SEM). Student's t-test was performed be-
tween the apoE3 and apoE4 groups (Figures 1, 2, 3, 4, 5).
Bonferroni correction was employed for multiple compar-
isons when needed. Further analysis of interactions be-
tween genotype and age or genotype and trial (Figures 6,
7,8) were performed utilizing two-way ANOVA tests using
STATISTICA software (Version 8.0 StatSoft, Inc., Tulsa,
USA).
Results
The extent to which the glutamatergic nerve terminals
are affected by apoE4 at a young age was first assessed by
immunohistochemical measurements of the levels of the
presynaptic vesicular glutamatergic transporter 1, VGlut1
(VGlut), in 4-month-old apoE4 and apoE3-targeted re-
placement mice. As shown in Figure 1, staining in the CA3
and CA1 subfields was pronounced in the dendritic layers
and sparse in the corresponding perikarya. Furthermore,
the intensity of the VGlut staining in the dendritic layers of
the CA3 and CA1 subfields was significantly lower in the
apoE4 than in the corresponding apoE3 mice (i.e. a de-
crease of 30 ± 4% in the stratum locidum of the CA3 in
the apoE4 mice p<0.0001 and of 40 ± 7.5% in the apical
and basal dendritic layers of the corresponding CA1 field:
p<0.001). VGlut staining in the DG, which was most pro-
nounced in the hilus, was also lower in the apoE4 mice
(a decrease of 26 ± 5.6%: p<0.001; Figure 1A). Immunoblot
experiments utilizing whole hippocampus homogenates
revealed, in accordance with the above immunohistochem-
ical results, that the levels of the VGlut immunoblot band
(mw = 60 kDa) were lower in the apoE4 than in the apoE3
mice (Figure 1B). It remains to be determined whether
additional presynaptic and/or postsynaptic glutamatergic
components are also affected by the apoE genotype.
The extent to which apoE4 affects hippocampal inhibi-
tory GABAergic synapses was investigated utilizing the
GABA synthesizing enzyme GAD67 as a marker. GAD67
Figure 1 The levels of the presynaptic gutamatergic transporter VGlut in hippocampal neurons of 4-month-old apoE3 and apoE4 mice.
(A) VGlut1 immunohistochemistry. Representative images (X20 magnification) of the indicated hippocampal subfields are presented on the left.
Quantification of the results (mean ± SEM: n=20 per group) of apoE3 mice (white bars) and apoE4 mice (black bars) was performed by
computerized image analysis as described in Materials and Methods and is shown on the right. *p<0.001 (for comparison of the results of the
apoE4 and apoE3 mice). Scale = 120 μ. (B) VGlut immunoblot. Representative immunoblots of homogenates of whole hippocampi of apoE3 and
apoE4 mice are presented on the left together with the GAPDH standard. Quantification of the results (mean ± SEM; n=10 per group) of apoE3
mice (white bars) and apoE4 mice (black bars) is depicted on the right. *p<0.001.
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rons [50,56]. As shown in Figure 2A, GAD67 levels in both
the perikarya and the dendritic layers of CA3 were not af-
fected by the apoE genotype. Similar results were obtained
in the corresponding CA1 and DG subfields andFigure 2 The levels of inhibitory neurons and synapses (GAD67) and
and apoE4 mice. (A) GAD67 immunohistochemistry. Representative image
Quantification of the results in the corresponding perikarya and dendritic fi
apoE4 mice (black bars) is shown on the right. Scale = 120 μ. (B) Synaptophy
the CA3 subfield are presented on the left. Quantification of the results (mean
(black bars) is shown on the right. Quantification of the GAD67 and synaptop
image analysis, as described in Materials and Methods. *p<0.005. Scale = 120following staining for Vgat (Vesicular GABA transporter) in
all hippocampal subfields (not shown). Immunohistochemi-
cal experiments with the general synaptic vesicle marker
synaptophysin revealed small apoE4-driven decreases in
CA3 (15 ± 3%; p=0.005; Figure 2B), as well as in CA1 (20 ±of the presynaptic marker synaptophysin in 4-month-old apoE3
s (X20 magnification) of the CA3 subfield are presented on the left.
elds (mean ± SEM; n=20 per group) of apoE3 mice (white bars) and
sin immunohistochemistry. Representative images (X20 magnification) of
± SEM; n=20 per group) of apoE3 mice (white bars) and apoE4 mice
hysin immunohistochemical results was performed by computerized
μ.
Figure 3 The levels of the mitochondrial proteins Tom40 and COX1 in hippocampal neurons of 4-month-old apoE3 and apoE4 mice.
(A) Tom40 immunohistochemistry. Representative images (X10 magnification) of the indicated hippocampal subfields are presented on the left.
Quantification of the results (mean ± SEM; n=8 per group) of apoE3 mice (white bars) and apoE4 mice (black bars) is shown on the right.
*p<0.05. Scale = 350 μ. (B) COX1 immunohistochemistry. Representative images (X10 magnification) of the indicated hippocampal subfields are
presented on the left. Quantification of the results (mean ± SEM; n=8 per group) of apoE3 mice (white bars) and apoE4 mice (black bars)
is shown on the right. *p<0.05. Scale = 350 μ. Quantification of the Tom40 and COX1 results was performed by computerized image analysis,
as described in Materials and Methods. (C) Representative images of CA3 at X100 magnification are shown. Scale = 30 μ. Inserts depict selected
neurons at X2 magnification. (D) Tom40 and COX1 immunoblots. Representative immunoblots of homogenates of hippocampal CA3 neurons of
apoE3 and apoE4 mice are presented on the left together with the GAPDH standard. Quantification of the results (mean ± SEM; n=5 per group)
of apoE3 mice (white bars) and apoE4 mice (black bars) is depicted on the right. *p<0.05.
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The finding that the effects of apoE4 on the general pre-
synaptic marker synaptophysin are less robust than the cor-
responding effects of apoE4 on VGlut (compare Figures 1
and 2) probably reflects the differential susceptibility of dif-
ferent nerve types (e.g., excitatory vs. inhibitory synapses)
to apoE4. Complementary measurements utilizing NeuN
immunohistochemistry revealed that apoE4 did not affect
the number and density of pyramidal and granular neurons
in any of the hippocampal subfields (not shown).
The effects of apoE4 on the mitochondria in the hippo-
campus were investigated immunohistochemically and byimmunoblot assays, utilizing the translocase of the outer
mitochondrial membrane protein, Tom40, and the electron
transport protein, COX1, as markers. The Tom40 immuno-
histochemistry results thus obtained are depicted in
Figure 3A. As shown, the intensity of staining of the apoE4
mice increased in CA3 (42 ± 15%; p=0.04) and in the DG
(88 ± 20%; p=0.004) relative to the corresponding apoE3
mice, but was not significantly affected in the CA1 subfield
(an increase of 7 ± 17%). The levels of COX1 were also ele-
vated by apoE4 (Figure 3B). This effect was specific to the
CA3 subfield (an increase of 143 ± 33% relative to the
apoE3 mice; p=0.03); moreover, there were no significant
Figure 4 The levels of Aβ42 in hippocampal neurons of 4-month-old apoE3 and apoE4 mice. (A) Representative images
(X10 magnification) of the indicated hippocampal fields stained with anti-Aβ42 are presented on the left. Quantification of the results
(mean ± SEM; n=20 per group) of apoE3 mice (white bars) and apoE4 mice (black bars) was performed by computerized image analysis, as
described in Materials and Methods, and is shown on the right. *p<0.05. Scale = 350 μ. (B) Representative images of CA3 at X100 magnification
are shown. Scale = 30 μ. Inserts depict selected neurons at X2 magnification. (C) Representative confocal images (X20 magnification) of the CA3
subfield of apoE3 and apoE4 mice stained with the pan anti-Aβ Ab 4G8. Scale = 120 μ. (D) Aβ X-42 ELISA. Quantification of Aβ42 levels in
4-month-old apoE3 and apoE4 mice was performed utilizing an ELISA kit. Results are presented as pictograms of Aβ42 per hippocampus. *p<0.05
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DG (18 ± 11%). Higher power micrographs showed the
expected punctate localization of Tom40 and COX1 in the
neuronal perikarya (Figure 3C). Immunoblot assays of the
CA3 subfield are depicted in Figure 3D. These experiments
revealed, in accordance with the immunohistochemical re-
sults, an elevation in the Tom40 (39 ± 8%, p=0.01) and
COX1 (72 ± 15%; p=0.01) levels in the apoE4 mice relative
to the apoE3 mice. It remains to be determined whether
these mitochondrial effects are due to direct effects of
apoE4 on the mitochondria or reflect a compensatory re-
sponse of the mitochondria to apoE4-induced stress.
It has been previously shown that apoE4 stimulates
the accumulation of Aβ42 in hippocampal neurons fol-
lowing pharmacological activation of the amyloid cas-
cade, which in turn, triggers synaptic impairments and
neurodegeneration [57]. We therefore examined whether
the presently observed neuronal effects of apoE4 in the
young apoE4 mice are also associated with accumulation
of Aβ42 in the affected neurons. As shown in Figure 4A,
the perikarya of CA1 and CA3 pyramidal neurons and
of the DG granular neurons stained positively for Aβ42.
This was obtained utilizing the AB5078P monoclonal-Ab (mAb), whose specificity to Aβ42 has previously
been confirmed [58]. In CA3 neurons the intensity of
staining was significantly higher in the apoE4 than in the
corresponding apoE3 mice (i.e. an increase of 98 ± 30%,
p<0.0005). The levels of Aβ42 in CA1 and DG were also
higher in the apoE4 mice compared with the apoE3
mice; however, these effects were smaller and less signifi-
cant (increases of 29 ± 15% in CA1, p=0.06; and of 28 ±
18% in DG; p=0.04). The cellular nature of the accumu-
lated Aβ42 was further ascertained by examining the sec-
tions at a higher magnification (Figure 4B). Similar results
were obtained utilizing an ELISA kit, and total hippocam-
pal homogenates (Figure 4D). The levels of Aβ42 in apoE4
mice were higher than in the corresponding apoE3 mice
(8.23±0.79 and 5.92±0.45 picograms (pg) of Aβ42 per mg
protein, respectively; p<0.05).
Control experiments revealed that the hippocampal
Aβ42 staining of the apoE4 mice was significantly higher
than that of a corresponding section from APP knock-
out (K.O.) mice, whereas the staining of the apoE3 mice
was only slightly higher than the background staining.
Additional controls revealed that the patterns of staining
for Aβ42 and APP (mAb 22C11) were different (see
Figure 5 Immunohistochemistry of tau phosphorylation and total tau levels in hippocampal neurons of 4-month-old apoE3 and apoE4
mice. (A) Tau phosphorylation immunohistochemistry utilizing AT-8. Representative images (X10 magnification) of the indicated hippocampal
subfields are presented on the left. Quantification of the results (mean ± SEM; n=20 per group) of apoE3 mice (white bars) and apoE4 mice (black bars)
was performed by computerized image analysis, as described in Materials and Methods, and is shown on the right. *p<0.001. Scale = 350 μ. (B) Total
tau levels immunohistochemistry utilizing H150. Representative images (X10 magnification) of the indicated hippocampal subfields are presented on
the left. Quantification of the results (mean ± SEM; n=20 per group) of apoE3 mice (white bars) and apoE4 mice (black bars) was performed by
computerized image analysis, and is shown on the right. Scale = 350 μ. (C) Tau phosphorylation immunohistochemistry utilizing AT100. Representative
images (X10 magnification) of the indicated hippocampal subfields are presented on the left. Quantification of the results (mean ± SEM; n=6 per
group) of apoE3 mice (white bars) and apoE4 mice (black bars) was performed by computerized image analysis, and is shown on the
right. Scale = 350 μ.
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of Aβ42 was also observed with the pan Aβ mAb 4G8
(Figure 4C). This Ab also revealed increased staining in
apoE4 than in apoE3 mice. This effect, however, was less
pronounced, which is probably due to the fact that in
addition to Aβ42, 4G8 also recognizes APP and other
forms of Aβ.
It has been suggested that tau plays an important role
in mediating the neuronal and cognitive pathological ef-
fects of apoE4 during aging [50]. The possibility that the
early synaptic and pathological effects of apoE4 in youngtargeted replacement mice are also associated with tau-
related changes was therefore examined. This was pur-
sued by measuring the effects of apoE4 on the phos-
phorylation level of tau. Hippocampal sections stained
with mAb AT8, which recognizes tau phosphorylated at
both Ser202 and Thr205 [59], are depicted in Figure 5A.
As shown, AT8 stained CA3 and CA1 pyramidal neurons
as well as the granular neurons of DG and the hilus. Im-
portantly, the intensity of AT8 staining observed in these
hippocampal subfields was significantly higher in the
apoE4 mice than in the apoE3 mice (i.e. an increase of
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CA1; p<0.001, and an increase of 64 ± 14% in the hilus of
DG; p<0.001; Figure 5A). Control experiments, utilizing
the phosphorylation-insensitive tau mAb H150, revealed a
staining pattern similar to that observed with AT8, but the
intensities of staining were the same in the apoE3 and
apoE4 mice (Figure 5B). Furthermore, the levels of the
phosphorylated tau epitope, which is recognized by mAb
AT100 (Thr212/Ser214) [60], were low, particularly in DG
and CA3, and were similar in the apoE3 and apoE4 mice
(Figure 5C). Taken together, these findings suggest that
hippocampal tau of 4-month-old apoE4 mice is hyper-
phosphorylated and that this effect is epitope specific.
Negative control experiments utilizing tau-K.O. mice re-
vealed that the observed staining is indeed specific to tau
(see Additional file 1: Figure S1). Additional experiments
revealed that the extent of tau phosphorylation as well as
the levels of VGlut and cellular Aβ42 in the entorhinal
cortex are not affected by apoE4, suggesting that the ef-
fects of apoE4 are specific to the hippocampus.
The extent to which the effects of apoE4 on tau, Aβ42,
VGlut and the mitochondria appear sequentially was as-
sessed by measuring the effects of apoE4 on these para-
meters in 1-month-old mice. The results thus obtained in
CA3 neurons and their comparison to the effects observed
in 4-month-old mice are depicted in Figure 6 (sections
from all age groups were stained together and the results
obtained are normalized relative to apoE3 at 4 months,
whose value was set at 1). Two-way ANOVA on the VGlut
results (Figure 6A) revealed a significant effect for apoE
genotype (p<0.02) and age (p<0.005) and a non-significant
effect for genotype×age (p=0.25). This suggests that the
levels of VGlut are lower in the apoE4 than in the apoE3
mice and that they both decrease similarly over time. The
results thus obtained with the mitochondrial markers
Tom40 and COX1 are depicted in Figure 6B. Two-way
ANOVA of the Tom40 results (Figure 6B) revealed a sig-
nificant effect for apoE genotype (p<0.01) and age (p<0.001)
and that the age dependency of the Tom40 levels of the
apoE4 and apoE3 mice were similar (p=0.5 for geno-
type×age). The COX1 levels of apoE4 mice (Figure 6A)
were also higher than those of the apoE3 mice (p<0.005 for
the effect of apoE genotype). It followed the same pattern
as that obtained with Tom40 except that in the case of
COX1 the increase with age was not statistically significant.
Taken together, these findings suggest that both age and
apoE4 independently cause a decrease in the levels of VGlut
and increase in the levels of the mitochondrial markers.
The effects of apoE genotype and age on Aβ42 levels
are depicted in Figure 6C. Two-way ANOVA of these re-
sults revealed a significant effect for genotype×age
(p<0.001). Further post hoc analysis revealed that the
levels of Aβ42 at 1 month in the apoE3 and apoE4 mice
were similar and that they decreased significantly withtime in the apoE3 mice and insignificantly increased in
the corresponding apoE4 mice. This yielded a significant
difference at 4 months between the Aβ42 levels of the
apoE4 and apoE3 mice (p<0.01).
The age dependency of tau phosphorylation in CA3 neu-
rons of the apoE3 and apoE4 mice is depicted in Figure 6C.
Two-way ANOVA of these results revealed a significant
effect for genotype×age (p<0.001). This was associated
with significantly elevated levels of phosphorylated tau in
the 1-month-old apoE3 mice relative to the corresponding
apoE4 mice (p<0.001) and with a significant age dependent
reduction in the levels of tau phosphorylation in the apoE3
mice (p<0.001). In contrast, the levels of tau phosphory-
lation in the apoE4 mice increased between 1 and 4 months
of age, however this effect was not statistically significant.
Thus, the pattern obtained is biphasic: at 1 month, tau
is hyperphosphorylated in the apoE3 relative to the apoE4
mice, whereas at 4 months the phosphorylation levels of
the apoE3 mice decrease and are consequently signifi-
cantly lower than those of the corresponding apoE4 mice.
The putative mechanisms that may underlie this biphasic
effect are presented in the discussion. However, regardless
of the mechanisms involved, these findings show that the
effects of the apoE genotype, which are reflected by tau
phosphorylation, also start at 1 month or before.
Taken together, these results define a time window
for the effects of apoE4 on CA3 neurons that occur at
1 month or before and are reflected by changes in tau
phosphorylation and the mitochondrial parameters. This
is then followed by presynaptic pathology and the accu-
mulation of neuronal Aβ42. Similar age-dependent pat-
terns were observed in CA1 and DG, where the tau and
mitochondrial changes preceded the decrease in VGlut
(not shown).
Measuring the effect of apoE4 on the apoE levels in
the hippocampus of 4-month-old mice revealed, in ac-
cordance with a previous reports [61,62] that they were
lower in the apoE4 than in the apoE3 mice (Figure 7A).
Similar results were obtained with 1-month-old mice,
whose apoE levels were, however, lower than those of
the corresponding 4-month-old mice. Confocal micros-
copy colocalization experiments revealed that in 1-month-
old mice most of the apoE was colocalized with astrocytes,
whereas in the 4-month-old mice, the fraction of apoE
associated with neuronal perikarya increased (Figure 7B).
Importantly, the relative distribution of apoE4 in these
compartments was not affected by the apoE genotype
(Figure 7B).
The effects of apoE4 on the cognitive performance of
young apoE4 mice were assessed utilizing a dry version
of the Morris Swim test in which water-deprived mice
are tested for their ability to learn the location of a
water-filled well. As shown in Figure 8, both the apoE3
and apoE4 mice learned the position of the water-filled
Figure 6 Time course of the effects of the apoE genotype in CA3 neurons of 1- and 4-month-old apoE3 and apoE4 mice. (A) The levels
of VGlut in apoE3 (white bars) and apoE4 (black bars) mice. *p<0.02 for the effect of apoE genotype and p<0.005 for the effect of age. (B) The
levels of the mitochondrial markers COX1 (left) and Tom40 (right) in apoE3 (white bars) and apoE4 (black bars) mice. *p<0.01 and p<0.002 of the
effect for apoE genotype on Tom40 and COX1 levels, respectively, and p<0.001 for the effect of age on Tom40. (C) The levels of AT8
phosphorylated tau (left) and Aβ42 (right) in apoE3 (white bars) and apoE4 (black bars) mice. Two-way ANOVA revealed a significant effect for
genotype×age for both the AT8 (p<0.0001) and Aβ42 (p<0.01) results. The significant post hoc comparisons of the effects of age and genotype
are denoted by the hash marks as follows: #p<0.05, ##p<0.01 and ###p<0.001. Results in each of the panels (n=8 mice per group) were obtained
at the same time and are presented relative to the 4-month-old apoE3 group.
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they reached a plateau of about 30 sec by days 6–8 (see
days 1 to 8 in Figure 8A). The water-filled well was then
moved to a new position and the mice were tested for
5 additional days (days 9–13 in Figure 8). As shown, the
performance of both groups deteriorated in the first
2 days after the position of the water-filled well was
changed. Following the deterioration, which was similar
in apoE3 and apoE4 mice, the performance of the mice
improved and this effect seemed to occur more rapidly
in apoE3 than in apoE4 mice. This trend was not statisti-
cally significant (repeated-measures ANOVA p=0.18 and
on the 4th day p=0.1). However, a separate analysis ofthe results obtained on the first and last of the 4 daily
runs during days 9–13 revealed significant differences.
As shown in Figure 8C, the performance of the apoE4
mice in the last run of each day was significantly im-
paired (repeated-measures ANOVA p=0.02 and on the
4th day p=0.01). Conversely, no differences between the
apoE3 and apoE4 mice were observed in the first run of
each day (repeated-measures ANOVA p=0.73 and on
the 4th day p=0.92; Figure 8B).
Further two-way ANOVA analysis of the effect for
apoE genotype and for trials revealed that genotype×trial
(p=0.02) had an effect (p<=0.02), thus confirming that the
effects of apoE4 are trial dependent. The performance in
Figure 7 The levels and spatial distribution of apoE in the hippocampus of 1- and 4-month-old apoE3 and apoE4 mice. (A) ApoE
immunoblots. Representative immunoblots of homogenates of whole hippocampi of 1- and 4-month-old apoE3 and apoE4 mice are presented
on the left together with the GAPDH standard. Quantification of the results (mean ± SEM; n=6 per group) of apoE3 mice (white bars) and apoE4
mice (black bars) is depicted on the right. *p<0.05. (B) Confocal microscopy utilizing the apoE (green); neuronal marker NeuN (red); and GFAP
(blue) antibodies. A representative section of the individual immunostainings and their superposition is presented. Colocalization of apoE with
astrocytes is shown in light blue in the right panel (white arrowheads), whereas colocalization of apoE with neurons is shown in yellow (black
arrowheads). Quantification of the relative percentage of apoE colocalized respectively with neurons and astrocytes (mean ± SEM; n=6 per group)
in 1- and 4-month-old apoE3 mice (white bars) and apoE4 mice (black bars) was performed by computerized image analysis, as described in
Materials and Methods, is presented on the right. Scale for left panel = 120 μ. Scale for the middle panel = 40 μ.
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whereas the performance in the last daily run is related to
short-term memory [63]. This suggests that the cognitive
deficit of the young apoE4 mice is related to impaired
short-term working memory.
Discussion
This study investigated the extent to which the early
pathological effects of apoE4, known to occur in man,
also occur in young apoE4-expressing mice. This re-
vealed that the levels of the presynaptic glutamatergic
transporter VGlut are lower in CA3, CA1, and DG hip-
pocampal neurons of 4-month-old apoE4-targetedreplacement mice than in the corresponding apoE3
mice. In contrast, the corresponding inhibitory
GABAergic nerve terminals and perikarya were not af-
fected by apoE genotype. This synaptic effect was associ-
ated with hyperphosphorylated tau in these hippocampal
subfields and with the accumulation of Aβ42 in CA3
neurons. Further experiments revealed that the mito-
chondrial markers Tom40 and COX1 were also elevated
by apoE4, and that the levels of Tom40, but not COX1,
were elevated in the DG. A summary of these findings is
presented in Table 1. Time-course studies revealed that
the apoE4-driven accumulation of Aβ42 and the associ-
ated decrease in VGlut develop after the age of 1 month
Figure 8 Performance in the dry version of the Morris water maze of 4-month-old apoE3 and apoE4 mice. (A) Average latency to the
water. Daily averages (4 runs per day) of apoE3 (white squares) and apoE4 (black squares) mice (n=7 per group) for 8 days with the water-filled
well in the first location and following the change in the position of the water-filled well (days 9–13). (B) Latency of the first run of each day
(days 9–13). (C) Latency of the last run of each day (days 9–13). *p<0.05. ANOVA reaveled a significant effect for genotype×trial (p<0.05).
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phosphorylation apoE-genotype specific effects.
The present finding that glutamatergic neurons are
negatively affected by apoE4 is in accordance with pre-
vious electrophysiological and anatomical observations







GAD67 +14±6 +14±7 +5±
(% increase) N.S. N.S. N
Tom40 +42±15 +7±
(% increase) P=0.04 N
COX1 +143±33 +17
(% increase) P=0.03 N
Tau (AT8) +150±21 +70
(% increase) P<0.0001 P<0
Aβ42 +95±20 +20
(% increase) P<0.001 N
N.S. = Not Significant.showing that apoE4 impairs glutamatergic synapses and
neuronal transmission [64-67]. Previous studies with
older apoE4 mice revealed that GABAergic neurons
are affected by apoE4 and that this effect develops with
age and is robust in 10-12-month-old mice [50]. Taken
together, the results suggest that glutamatergic neuronss
CA1 DG
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followed by subsequent GABAergic pathology. The find-
ing that other components of the glutamatergic synapse,
such as synaptic spines [65], postsynaptic glutamatergic
receptors [64,68], and the scaffold protein PSD-95 [69]
are decreased by apoE4 suggests that the presently ob-
served apoE4-driven decrease in VGlut is not specific to
this molecule and is associated with impaired gluta-
matergic function. It is important to note that the
magnitude and direction of the effects of apoE4 are af-
fected by diet. Accordingly, unlike presently observed,
the levels of VGlut are elevated by apoE4 in mice fed a
DHA-depleted diet but were the same in apoE3 and
apoE4 mice that were fed a high-DHA diet [54]. The
mechanisms underlying the effects of lipids on the bal-
ance between the presently observed apoE4-driven
reduction in VGlut levels and the effect observed in
DHA-depleted apoE4 mice remain to be determined.
However, since apoE4-driven synaptic loss seems to be
accompanied by an increase in synaptic area [70], it is
possible that the overall effect of apoE4 on VGlut, and
its polarity reflect the extent to which diet affects these
processes. Further sub-cellular fractionation studies are
required in order to unravel the specifics of the mech-
anism underlying the effect of apoE4 on the life cycle
of VGlut.
The present finding that the mitochondria are affected
by apoE4 in young mice is in accordance with previous
findings, such as reduced COX1 activity in the brains of
young adult apoE4 carriers [46], a genetic association
between apoE4 and the TOMM40 gene [48,71], and
the in vitro effects of apoE4 on mitochondrial activity
[47,72]. However, since the presently observed mito-
chondria-related effects of apoE4 are up-regulation of
the levels of the mitochondrial proteins COX1 and
Tom40, it is possible that this effect represents a com-
pensatory defense response to the related pathological
effects of apoE4. Accordingly, the observed elevation
in COX1 and Tom40 levels, which is already apparent
in the CA3 neurons at the age of 1 month, may re-
flect activation of a defense mechanism, which at 1
month, but not at 4 months, is able to counteract the
effect of apoE4 on Aβ and VGlut. It is, however, pos-
sible that the observed up-regulation of the mitochon-
drial proteins reflects an apoE4-dependent functional
mitochondrial abnormality. The effects of apoE4 on the
mitochondria are neuron specific and occur mainly in CA3
neurons. It remains to be determined whether this is due to
specific properties of the mitochondria of the CA3 neurons,
which render them more responsive to stressful stimuli, or
to increased susceptibility of the CA3 neurons to apoE4.
The finding that the levels of Aβ42 and phosphorylated tau
are also highest in CA3 neurons is consistent with both of
these interpretations.The present finding that apoE4 increases the accumula-
tion of neuronal Aβ42 and hyperphosphorylated tau in
hippocampal neurons is in agreement with previous ob-
servations. However, these studies rely on mechanistic
hypothesis-driven models, such as APP and apoE4 double
transgenes [73], pharmacological activation of the amyloid
cascade for Aβ [57], and transgenic mice that express tau
in neurons [43,44,74]. The novelty of the present observa-
tions is that the apoE4-driven accumulation of neuronal
Aβ42 and hyperphosphorylated tau occurs spontaneously
in the absence of any tau or Aβ-related manipulations.
These findings raise important questions regarding the
mechanisms by which apoE4 triggers the accumulation of
Aβ42 and hyperphosphorylated tau in hippocampal neu-
rons and the possible role of these molecules in mediating
the synaptic pathological effects of apoE4. Previous studies
have shown that apoE4 can enhance the effects of Aβ by
several mechanisms. These include decreased degradation
and clearance of human Aβ42 from the brain [75-78], as
well as stimulation of the intraneuronal accumulation of
mouse Aβ [32]. The fact that the apoE4-driven accumu-
lation of Aβ42 is neuron specific and is highest in CA3
neurons argues against a general hippocampal mechanism
and favors a CA3-based neuron-specific mechanism. The
intraneuronal accumulation of Aβ can be driven by apoE
receptors [79] whose levels are affected by apoE genotype.
Aβ is localized to glutamatergic synapses [80,81] and can
decrease synaptic activity [82]. It is thus possible that Aβ42
plays a role in the observed synaptic pathology of the CA3
neurons via such a mechanism. However, since the loss of
VGlut in the CA1 and DG, which is similar to that ob-
served in CA3 (Figure 1), is associated with only a small in-
crease in neuronal Aβ42 (Figure 4), additional non-Aβ42
-driven mechanisms may also be involved.
ApoE4 can affect tau phosphorylation either directly
by binding to tau [83], or via apoE receptors and down-
stream signaling, which can affect kinases such as GSK3β
[84-86]. The finding that at 1 month, unlike at 4 months,
tau is more phosphorylated in the apoE3 than in the
apoE4 mice and that this age-dependent effect is due to
a specific decrease in tau phosphorylation between 1 and
4 months in the apoE3, with no change in the apoE4 mice,
suggests that a mechanism responsible for tau phosphor-
ylation and subsequent dephosphorylation is missing in
the apoE4 mice. Tau is transiently hyperphosphorylated at
the AT8 epitopes (202/205) and numerous other sites dur-
ing neuronal development [87-89]. It is thus possible that
the decreased AT8 phosphorylation in 1-month-old mice
(see Figure 5) reflects developmental effects of apoE4.
Additional studies starting at younger ages and utilizing
embryos are required in order to further characterize this
effect of apoE on tau phosphorylation and for identifying
putative kinases and phosphatases that may play a role in
mediating the isoform-specific effects of apoE on tau
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merous pathological effects including depolymerization of
microtubules and subsequent impairments of axonal
transport [90], as well as the formation of cytotoxic tau ag-
gregates [91]. Since the excess of 202/205 tau phosphoryl-
ation and the reduced VGlut levels are apparent in CA3,
CA1, and DG neurons, it is possible that such tau-related
mechanisms may mediate the effects of apoE4 on the
glutamatergic nerve terminals.
The molecular mechanism underlying the presently
observed effects of apoE4 on VGlut, Aβ42, AT8 tau
phosphorylation as well as the mitochondrial parameters
are not known. Preliminary findings suggest that the
levels of the apoE receptor apoER2 in the CA3, CA1,
and DG hippocampal neurons are markedly reduced in
the apoE4 mice (to be published). This is in accordance
with previous observations [64] and suggests that the
observed effects of apoE4 may be mediated by impaired
apoER2 signaling. It remains to be determined whether
these effects are triggered via a loss of function mechan-
ism (e.g., apoE4 < apoE3. see Figure 7), or via a gain of
toxic function mechanism.
The present finding that 4-month-old apoE4 mice are
cognitively impaired in dry maze is in accordance with
the recent finding that the learning and memory perfor-
mances of young apoE4 mice in the fear conditioning
paradigm is also impaired [92].
It has recently been shown that the performance of
rats in a spatial navigation test across days reflects the
efficacy of reference memory, whereas the corresponding
performance within a testing session is a measure of
working memory [63]. Accordingly, the present finding
that the performance of the apoE4 mice is impaired in
the last but not the first daily run following the change
in position of the water-filled well (Figures 6B and 6C)
suggests that the working memory of the apoE4 mice is
impaired. It is, however, possible that additional behav-
ioral features such as motivation or susceptibility to
stress also affect the performance of the apoE4 mice.
The neurochemical findings that the isoform-specific
effects of apoE4 on tau phosphorylation and on the
mitochondrial parameters are already apparent at the
age of 1 month, whereas the associated accumulation of
Aβ and glutamatergic pathology evolve later, suggest that
tau phosphorylation and the mitochondrial changes re-
flect early apoE4-driven processes that are followed by
the Aβ and synaptic changes. These processes are par-
ticularly robust in CA3 neurons. The causal relationship
between the different neurochemical effects of apoE4
and the extent to which they mediate the behavioral ef-
fects of apoE4 remain to be determined.
The extent to which the observed effects of apoE4 are
mediated by either gain or loss of function is not known.
We have recently shown that the pathological synergisticinteractions between apoE4 and Aβ are more pronounced
in apoE4 than in apoE-K.O. mice, suggesting that the inter-
action between apoE4 and Aβ is mediated via a gain of
toxicity mechanism [93]. However, since the levels of apoE
are lower in the apoE4 than in the apoE3 mice, we cannot
rule out the possibility that a loss of function mechanism
also plays a role in mediating the effects of apoE4.
Recent in vivo and in vitro studies revealed that apoE4
impairs the blood brain barrier (BBB) [94,95]. Since these
effects are already apparent at a very young age in apoE4-
targeted replacement mice [95], it is possible that impair-
ments in the BBB play a role in initiating the effects of
apoE4 on Aβ, tau, and VGlut. However, since the effects
presented are neuron specific (see Figures 1, 3, and 4),
additional neuronal mechanisms, downstream to the BBB,
must also play a role.
Gene expression studies of AD brains revealed that
apoE4 is associated with altered transcription of multiple
gene transcripts including the down-regulation of genes
related to synaptic plasticity and function [42,96]. Recent
studies suggest that in addition to the effects of apoE4
on brains of the aged population [97,98], it also affects
the brains of apparently healthy younger apoE4 carriers
[8,31,46,99-101]. Furthermore, it has been recently shown
that the human brains of neonates are also affected by
apoE4 [102]. Accordingly, it is possible that the effects of
apoE4, which are already apparent in the developing brain
at a young age, may play a role in the subsequent induc-
tion of the disease later in life. The present study, which
focuses on brain neurons in young apoE4 mice, and recent
complementary reports that focused on the vasculature
[69,94] and glia [69,94] of these mice, are consistent with
this hypothesis, and suggest that the pathological effects of
apoE4 start much earlier in life than previously thought.
Another important implication of these findings is that
young apoE4 mice provide an unbiased model for study-
ing the mechanisms underlying the pathological effects
of apoE4 in the absence of any mechanism-driven ma-
nipulations. However, the jury is still out regarding the
cellular and molecular mechanisms that mediate the ef-
fects of apoE4 in vivo and whether they are due to gain of
toxic function and/or to a loss of function. The present
model, combined with the recently described pharmaco-
logical manipulations that elevate the total level of brain
apoE [103] and of mAbs that are directed specifically at
apoE4 [104], now provide the means to address these im-
portant issues.
In conclusion, the present findings show that the path-
ological effects of apoE4 in targeted replacement mice
are already apparent in young 4-month-old mice and
that at this stage the glutamatergic system is particularly
susceptible to apoE4. These effects are associated with
the accumulation of neuronal Aβ42, hyperphosphor-
ylated tau, and an increase in mitochondrial markers.
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already apparent at a very young age and that Aβ42, tau,
and the mitochondria play a role in mediating the ob-
served early apoE4-driven synaptic pathology. Young
apoE4 mice thus provide an unbiased and hypothesis-
independent model for studying the early pathological
effects of apoE4.Additional file
Additional file 1: Figure S1. Legend: Negative controls of the AT8 tau
and Aβ42 immunohistochemical staining. (A) AT8 staining of
hippocampal sections of tau-K.O. (Jackson #007251) and WT mice
showing that staining is absent in the tau KO mice. Scale = 300 μ.
(B) Aβ42 staining of hippocampal sections of APP-K.O. mice and WT mice
showing that staining is absent in the APP-K.O. mice. The APP-K.O mice
were kindly provided by Prof. H. Muller. Scale = 300 μ. (B) Aβ42 staining
of hippocampal sections of APP-K.O. mice and WT mice showing that
staining is absent in the tau KO mice. Scale = 300 μ. (C) Representative
image of hippocampal CA3 neurons of apoE4 mice co-stained for Aβ42
and APP (mAb directed against N-teminal APP, 22C11). As can be seen,
the patterns of staining of the 2 Abs are different (less than 15% of Aβ42
is colocalized to APP). Similar results were obtained with corresponding
sections from apoE3 mice. Scale = 30 μ.Competing interests
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